Clin Oncol | Volume 7, Issue 1 | Mini Review | Open Access

Advancing Theranostics’ Potential for Precision Medicine

Subhash Kheruka*, Naema Al Maymani*, Noura Al Makhmari, Tasnim Al Rahii, Huoda Al Saidi, Khulood Al Riyami, Rashid Al Sukaiti and Vipin V Jayakrishnan

Department of Radiology and Nuclear Medicine, Sultan Qaboos Comprehensive Cancer Care and Research Centre, Oman

*Correspondance to: Subhash Kheruka 

Fulltext PDF


Theranostics is a fascinating field of molecular medicine. Theranostic uses targeted pharmaceuticals for both imaging and treating cancer, made feasible by molecular imaging methods like PET and SPECT (SPECT). Patients with cancer may benefit from its ability to identify subgroups that respond to targeted treatment. And doctors admire its achievements and promise to help them
manage illnesses more efficiently by matching patients with the most effective medications.
Industry leaders are improving molecular imaging technology and seeking innovative tracers for targeted therapies. They provide access to new drugs and push the limits of molecular imaging using PET/CT and SPECT/CT. New molecular imaging technology provides additional imaging data for processing and AI-powered automated tools and reconstruction algorithms to aid clinicians
in making a difficult diagnosis. Theranostics uses molecular imaging to non-invasively evaluate drug uptake, tumor tissue, and therapy response.
With extensive data, theranostic target pairs have been established, confirmed, and successfully used to treat neuroendocrine tumors, lymphomas, neuroblastomas, and, more recently, various forms of the prostate.


PET; SPECT; Thranostic; AI


Kheruka S, Al Maymani N, Al Makhmari N, Al Rahii T, HAl Saidi T, Al Riyami K, et al. Advancing Theranostics’ Potential for Precision Medicine. Clin Oncol. 2022;7:1945..

Subscribe to Our Newsletter